Volume 3.07 | Feb 21

Hematopoiesis News 3.07, February 21, 2012
Hematopoiesis News
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
Osteoclasts Promote the Formation of Hematopoietic Stem Cell Niches in the Bone Marrow
Researchers used the oc/oc mouse, a mouse model with impaired endochondral ossification caused by a loss of osteoclast (OCL) activity, to investigate the role of osteoblasts and OCLs in the hematopoietic stem cell niche formation. [J Exp Med] Abstract

Free Wallchart: Identification Of Colonies Derived From Mouse Hematopoietic Progenitors
PUBLICATIONS (Ranked by Impact Factor of the Journal)

Lin28b Reprograms Adult Bone Marrow Hematopoietic Progenitors to Mediate Fetal-Like Lymphopoiesis
Scientists demonstrate that ectopic expression of Lin28 reprograms hematopoietic stem–progenitor cells from adult bone marrow, endowing them with the ability to mediate multilineage reconstitution that resembles fetal lymphopoiesis, including increased development of B-1a, marginal zone B, gamma/delta T cells, and natural killer T cells. [Science] Abstract

Lethal Myelofibrosis Induced by Bmi1-Deficient Hematopoietic Cells Unveils a Tumor Suppressor Function of the Polycomb Group Genes
Here, researchers show that loss of another polycomb-group gene, Bmi1, causes pathological hematopoiesis similar to primary myelofibrosis. [J Exp Med] Abstract

The THPO/MPL/Bcl-xL Pathway Is Essential for Survival and Self-Renewal in Human Pre-Leukemia Induced by AML1-ETO
In this report, investigators show that Bcl-xL is upregulated in AML1-ETO cells and plays an essential role in their survival and self-renewal. [Blood] Abstract

FOXO1 Is a Tumor Suppressor in Classical Hodgkin Lymphoma
Scientists found that in classical Hodgkin lymphoma cell lines FOXO1 is inactivated by multiple mechanisms, including constitutive activation of AKT/PKB and MAPK/ERK kinases and up-regulation of microRNAs miR-96, miR-182, and miR-183. [Blood] Abstract

Depletion of RUNX1/ETO in t(8;21) AML Cells Leads to Genome-Wide Changes in Chromatin Structure and Transcription Factor Binding
To obtain insights into RUNX1/ETO-dependant alterations of the epigenetic landscape, researchers measured genome-wide RUNX1- and RUNX1/ETO-bound regions in t(8;21) cells and assessed to what extent the effects of RUNX1/ETO on the epigenome depend on its continued expression in established leukemic cells. [Leukemia] Abstract

Valproic Acid Induces Differentiation and Transient Tumor Regression, but Spares Leukemia-Initiating Activity in Mouse Models of APL
Investigators have used several models of PML-RARA-driven acute promyelocytic leukemia (APL) to analyze the in vivo effects of valproic acid, a well-characterized histone deacetylase inhibitors. [Leukemia] Abstract

Alpharetroviral Self-Inactivating Vectors: Long-Term Transgene Expression in Murine Hematopoietic Cells and Low Genotoxicity
In a murine bone marrow transplantation model scientists compared alpharetroviral, gammaretroviral, and lentiviral self-inactivating vectors and showed that all vectors transduced hematopoietic stem cells, leading to comparable, sustained multilineage transgene expression in primary and secondary transplanted mice. [Mol Ther] Abstract

Reactive Oxygen Species and Aldehyde Dehydrogenase Activity in Hodgkin Lymphoma Cells
Findings show that aldehyde dehydrogenase-high and reactive oxygen species-low cells share cancer-initiating cell (CIC)-like potential, but they differ in their cell cycle status, suggesting that CICs are comprised of cells with heterogeneous characteristics. [Lab Invest] Abstract

Tet2 Disruption Leads to Enhanced Self-Renewal and Altered Differentiation of Fetal Liver Hematopoietic Stem Cells
Results demonstrate that ten-eleven translocation 2 (Tet2) plays a critical role in homeostasis of HSCs and hematopoietic progenitor cells not only in the bone marrow, but also in fetal liver. [Sci Rep] Abstract


Risk Stratification-Directed Donor Lymphocyte Infusion Could Reduce Relapse of Standard-Risk Acute Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation
Investigators prospectively studied the impact of risk stratification-directed interventions for minimal residual disease on relapse and disease-free survival in 814 persons with standard-risk acute leukemia receiving allotransplants in 1st or 2nd complete remission. [Blood] Abstract

A Phase II Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
This multicenter phase II study investigated the combination of rituximab-ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for stage II-IV untreated classical Hodgkin lymphoma. [Blood] Abstract

Efficacy and Safety of Hematopoietic Stem Cell Remobilization with Plerixafor+G-CSF in Adult Patients with Germ Cell Tumors
Herein, scientists describe a retrospective study examining safety and efficacy of plerixafor in combination with G-CSF for patients with germ cell tumors who had previously failed stem cell collection. [Bone Marrow Transplant] Abstract

Improve Quality Control and Regulatory Compliance. Watch the video to see how StemLab can help.
ARIAD Announces Issuance of Key U.S. Patent on Ponatinib
ARIAD Pharmaceuticals, Inc. announced that the United States Patent and Trademark Office has granted U.S. Patent No. 8,114,874 entitled, “Substituted Acetylenic Imidazo[1,2-B] Pyridazine Compounds as Kinase Inhibitors,” which provides composition-of-matter patent protection through at least December 22, 2026 for ARIAD’s investigational pan-BCR-ABL inhibitor, ponatinib. [ARIAD Pharmaceuticals, Inc.] Press Release

Cellerant Therapeutics Appoints Lowell E. Sears to Board of Directors
Cellerant Therapeutics Inc. announced that Lowell E. Sears joined its Board of Directors. [BusinessWire]
Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)
Center for Biologics Evaluation and Research (United States)
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Drug Discovery World Asia
March 19-22, 2012
Singapore, Singapore

Visit our events page to see a complete list of events in the hematopoietic community

Scientist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist (STEMCELL Technologies Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies Inc.)

Business Analyst – Product Management (STEMSOFT Software Inc.)

Postdoctoral/Research Associate (Children’s Memorial Research Center)

Pediatric Faculty – Hematology/Oncology Stem Cell Sciences (The University of Chicago)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe,
Middle East to Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us